RT Journal Article
T1 Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia
A1 Gudiol, Carlota
A1 Royo-Cebrecos, Cristina
A1 Abdala, Edson
A1 Akova, Murat
A1 Alvarez, Rocio
A1 Maestro-de la Calle, Guillermo
A1 Cano, Angela
A1 Cervera, Carlos
A1 Clemente, Wanessa T.
A1 Martin-Davila, Pilar
A1 Freifeld, Alison
A1 Gomez, Lucia
A1 Gottlieb, Thomas
A1 Gurgui, Merce
A1 Herrera, Fabian
A1 Manzur, Adriana
A1 Maschmeyer, Georg
A1 Meije, Yolanda
A1 Montejo, Miguel
A1 Peghin, Maddalena
A1 Rodriguez-Bano, Jesus
A1 Ruiz-Camps, Isabel
A1 Sukiennik, Teresa C.
A1 Tebe, Cristian
A1 Carratala, Jordi
K1 ESBLs
K1 Bloodstream infection
K1 Neutropenia
K1 Beta-lactam/beta-lactamase inhibitors
K1 Mortality
K1 Escherichia-coli
AB beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.
PB American Society for Microbiology
SN 0066-4804
YR 2017
FD 2017-04-27
LK http://hdl.handle.net/10668/18998
UL http://hdl.handle.net/10668/18998
LA en
NO Gudiol C, Royo-Cebrecos C, Abdala E, Akova M, Álvarez R, Maestro-de la Calle G, et al. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00164-17
NO We thank the ESGBIS and the ESGICH study groups for supporting the study.This study was supported by Ministerio de Economía y Competitividad, Instituto deSalud Carlos III— cofinanced by European Development Regional Fund “A way toachieve Europe” EDRF, Spanish Network for the Research in Infectious Diseases (REIPIRD12/0015)
DS RISalud
RD Apr 6, 2025